human cell microarray platform (Charles River Laboratories)
90
Structured Review
Charles River Laboratories
human cell microarray platform
Human Cell Microarray Platform, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cell+microarray+platform/human+cell+microarray/pm39871795-209-16-15
Average 90 stars, based on 1 article reviews
Human Cell Microarray Platform, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cell+microarray+platform/human+cell+microarray/pm39871795-209-16-15
Average 90 stars, based on 1 article reviews
human cell microarray platform - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Construct:Article Title: Applications of Cell-Based Protein Array Technology to Preclinical Safety Assessment of Biological Products. Article Snippet: Off-target evaluation is essential in preclinical safety assessments of novel biotherapeutics, supporting lead molecule selection, endpoint selection in toxicology studies, and regulatory requirements for first-in-human trials.. Off-target interaction of a therapeutic antibody and antibody derivatives has been historically assessed via the Tissue Cross-Reactivity (TCR) study, in which the candidate molecule is used as a reagent in immunohistochemistry (IHC) to assess binding of the candidate molecule to a panel of human tissue sections.. The TCR approach is limited by the performance of the therapeutic as an IHC reagent, which is often suboptimal to outright infeasible. Microarray:Article Title: Applications of Cell-Based Protein Array Technology to Preclinical Safety Assessment of Biological Products. Article Snippet: Off-target evaluation is essential in preclinical safety assessments of novel biotherapeutics, supporting lead molecule selection, endpoint selection in toxicology studies, and regulatory requirements for first-in-human trials.. Off-target interaction of a therapeutic antibody and antibody derivatives has been historically assessed via the Tissue Cross-Reactivity (TCR) study, in which the candidate molecule is used as a reagent in immunohistochemistry (IHC) to assess binding of the candidate molecule to a panel of human tissue sections.. The TCR approach is limited by the performance of the therapeutic as an IHC reagent, which is often suboptimal to outright infeasible. |